| Somatotropin deficiency
Humatrope vs Ngenla
Side-by-side clinical, coverage, and cost comparison for somatotropin deficiency.Deep comparison between: Humatrope vs Ngenla with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNgenla has a higher rate of injection site reactions vs Humatrope based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ngenla but not Humatrope, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Humatrope
Ngenla
At A Glance
SC injection
Daily
Recombinant human growth hormone
SC injection
Once weekly
Growth hormone analog
Indications
- Somatotropin deficiency
- Turner Syndrome
- Short Stature Homeobox Deficiency
- Growth retardation
- Somatotropin deficiency
Dosing
Somatotropin deficiency (pediatric) 0.18 mg/kg/week to 0.3 mg/kg/week divided into equal doses given 6 or 7 days per week by SC injection.
Somatotropin deficiency (adult) Non-weight based: initiate at approximately 0.2 mg/day (range 0.15-0.3 mg/day), increase every 1-2 months by 0.1-0.2 mg/day per patient requirements; weight-based (not for obese patients): initiate at 0.006 mg/kg/day up to 0.0125 mg/kg/day; daily SC injection.
Turner Syndrome Up to 0.375 mg/kg/week divided into equal doses given 6 or 7 days per week by SC injection.
Short Stature Homeobox Deficiency 0.35 mg/kg/week (0.05 mg/kg/day) by SC injection.
Growth retardation Idiopathic Short Stature: up to 0.37 mg/kg/week; Small for Gestational Age: up to 0.47 mg/kg/week; divided into equal doses given 6 or 7 days per week by SC injection.
Somatotropin deficiency 0.66 mg/kg based on actual body weight administered SC once weekly; individualize dosage based on growth response. When switching from daily growth hormone, initiate NGENLA on the day following the last daily injection.
Contraindications
- Acute critical illness after open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
- Prader-Willi syndrome in pediatric patients who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment
- Active malignancy
- Known hypersensitivity to somatropin or any excipient in HUMATROPE
- Active proliferative or severe non-proliferative diabetic retinopathy
- Closed epiphyses in pediatric patients
- Acute critical illness after open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
- Hypersensitivity to somatrogon-ghla or any excipient in NGENLA
- Closed epiphyses
- Active malignancy
- Active proliferative or severe non-proliferative diabetic retinopathy
- Prader-Willi syndrome with severe obesity, history of upper airway obstruction or sleep apnea, or severe respiratory impairment
Adverse Reactions
Most common (>=5%) Edema, arthralgia, paresthesia, myalgia, pain, peripheral edema, headache, hypertension, rhinitis, back pain (adults); hypothyroidism, allergic reaction, arthralgia, bone disorder, injection site pain (pediatric GHD).
Serious Increased mortality in acute critical illness, fatalities in Prader-Willi syndrome, neoplasms, glucose intolerance and diabetes mellitus, intracranial hypertension, severe hypersensitivity, fluid retention, hypoadrenalism, hypothyroidism, slipped capital femoral epiphysis, scoliosis progression, pancreatitis, lipoatrophy.
Postmarketing Anaphylactic reactions, angioedema, increase in size or number of cutaneous nevi, gynecomastia, pancreatitis, new-onset type 2 diabetes mellitus, osteonecrosis, leukemia.
Most common (>=5%) Injection site reactions, nasopharyngitis, headache, pyrexia, anemia, cough, vomiting, hypothyroidism, abdominal pain, rash, oropharyngeal pain
Serious Increased mortality in acute critical illness, severe hypersensitivity, increased risk of neoplasm, glucose intolerance and diabetes mellitus, intracranial hypertension, fluid retention, hypoadrenalism, hypothyroidism, slipped capital femoral epiphysis, progression of preexisting scoliosis, pancreatitis, lipoatrophy, sudden death in pediatric patients with Prader-Willi syndrome
Postmarketing Osteonecrosis in pediatric patients
Pharmacology
Somatropin is a recombinant human growth hormone that binds dimeric GH receptors on target tissue cell membranes, triggering intracellular signal transduction and induction of GH-dependent proteins (IGF-1, IGFBP-3, acid-labile subunit), with direct and IGF-1-mediated effects including stimulation of chondrocyte differentiation and proliferation, hepatic glucose output, protein synthesis, and lipolysis, thereby promoting skeletal and linear growth in pediatric patients with GH deficiency.
Somatrogon-ghla is a human growth hormone analog that binds to the GH receptor and activates the STAT5b signaling pathway, increasing serum IGF-1 concentrations and stimulating linear growth and metabolic changes in pediatric patients with growth hormone deficiency.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Humatrope
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (10/12)
Ngenla
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Humatrope
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Ngenla
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Humatrope
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Ngenla
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Growth Hormone Deficiency
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0/momo
Ngenla Copay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HumatropeView full Humatrope profile
NgenlaView full Ngenla profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.